ACMR · ACM Research, Inc.

The thesis

ACM Research's China chip-tool backlog is still growing, but the shares closed at $51.97 on 27 October 2026, 59.0% below the 52-week high of $126.89 and under the $55 level the previous note named. The preliminary third-quarter results due 28 October 2026 and the full results on 5 November 2026 decide whether orders are turning into revenue.

The adjusted close was $61.12 on 14 October 2026 and is now $51.97. The 14-day relative strength index (a 0-100 momentum gauge) stands at 19.1, deep in oversold territory, and the three-month price change is -33.9%. No company-specific negative news has appeared in that stretch. The only company item since the previous note is a 22 October 2026 product update: ACM said its Hot SPM (sulfuric acid-peroxide mixture) cleaning system passed foundry verification and adds 70% sulfuric acid recycling.

The narrative is maturing: the backlog story is well known, and the buying that followed the 30 September 2026 backlog release has fully reversed. The case rests on Q3 revenue and gross margin matching the fiscal 2026 outlook of $1.125-$1.175 billion that management set on 7 August 2026.

Bullish and bearish views on ACM Research, Inc.

The bull case on ACM Research, Inc. (ACMR), in brief: Backlog is growing fast. The bear case: The price broke the previous note's level.

Bull case

• Backlog is growing fast. ACM Shanghai reported RMB 17.1 billion of backlog on 29 September 2026, up 88.2% year over year, in a GlobeNewswire release dated 30 September 2026.
• Q2 revenue beat and guidance rose. Q2 2026 revenue was $292.9 million, up 36.0% year over year, and the fiscal 2026 outlook was raised to $1.125-$1.175 billion, per the 7 August 2026 release.
• Brokers sit far above the price. MarketBeat on 13 October 2026 showed five Buy ratings, one Hold and an average target of $122.75, and reported that Morgan Stanley's target is $130.
• Product validation continues. The 22 October 2026 company release says the Hot SPM system was verified at a foundry and cuts sulfuric acid use, which supports tool demand in cleaning.
• Selling pressure looks extreme. The relative strength index of 19.1 on 27 October 2026 compares with 64.5 on 1 October 2026.

Bear case

• The price broke the previous note's level. The $51.97 close of 27 October 2026 is below the $55 level in the previous note and below the $61.12 close of 14 October 2026.
• Margins narrowed as revenue grew. Q2 2026 gross margin excluding stock-based compensation was 46.0%, against 48.7% a year earlier, per the 7 August 2026 release. Management's stated band is 42%-48%.
• Insiders sold into the rally. MarketBeat reported on 13 October 2026, from SEC Form 4 filings, that CEO David Wang sold 70,000 shares (about $5.2 million) in September and director Haiping Dun sold 5,000 shares in August.
• Backlog is not revenue. The 30 September 2026 release says backlog includes tools shipped but awaiting revenue recognition and may not convert fully to revenue.
• Dilution and export controls remain open. ACM Shanghai's Hong Kong share offering was authorised on 26 May 2026 for 24 months with no pricing date. ACM subsidiaries have been inside the US export-control net since December 2024.

Price setup

The adjusted close was $51.97 on 27 October 2026, against a 52-week high of $126.89. The shares have lost 33.9% over three months. MarketBeat gives a beta of 2.09 (13 October 2026), so moves in the semiconductor sector are amplified.

The 50-day moving average was $75.98 and the 200-day was $75.12 on 13 October 2026, per MarketBeat, and the June low close was $76.29. All three sit far above the current price, so the shares trade in a zone with no recent closing history to mark support. A reading of 19.1 on the relative strength index has historically been followed by sharp rebounds in many stocks, but the reading shows only how fast the fall has been.

Crowding evidence points to a stretched, not a crowded, stock: heavy insider sales were reported in August and September, and the earnings date is within days. The next closing levels to watch are $55, the level now above the price, and $61.12, the 14 October 2026 close.

Catalysts, next 30 days

• No fixed date: Hong Kong pricing or listing application for the ACM Shanghai share offering.
• No fixed date: Any US export-control or Entity List action naming ACM Research (Shanghai).

Elapsed catalysts

• 28 October 2026: Preliminary Q3 2026 results before the US open, as announced by ACM on 30 September 2026. ACM Shanghai reports after the China close. This is the first hard revenue read since the August raise. Its text was not available when this note was written. (passed 9d ago)
• 5 November 2026: Full Q3 2026 results and call at 8:00 a.m. Eastern, per ACM's 19 October 2026 release as listed by Rava. This settles Q3 gross margin against the 42%-48% band and whether the $1.125-$1.175 billion outlook holds. (passed 1d ago)

What would change the view

The case breaks if Q3 gross margin excluding stock-based compensation falls under 42%, the floor of management's band, or if the fiscal 2026 revenue outlook is cut below $1.125 billion. Either would show backlog is not converting at the pace the guidance needs. A Hong Kong offering priced at a deep discount, or a new export-control action naming ACM, would also break it.

On price, a daily close below $45 would extend the post-September decline further. A stronger case would need Q3 revenue at or above the pace the guidance implies, with margin inside the 42%-48% band and a close back above $61.12.

What it trades with

ACM Shanghai trades separately in China (STAR Market 688082) and can reprice before the US line opens. The shares move with Chinese chip-tool localization, memory capital spending and US-China export-control headlines. Beta of 2.09 means the shares have swung roughly twice as far as the market in either direction. Other wafer-fab equipment makers with China exposure react to the same control news, but ACM has no theme peer with matching backlog reporting.